<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/ProjectMundo/style/jats-html.xsl"?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-024-52894-2
   </article-id>
   <article-id pub-id-type="manuscript">
    52894
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-024-52894-2
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/53/2423
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/308/174
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/699/67
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /82/58
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Plasma proteomic and polygenic profiling improve risk stratification and personalized screening for colorectal cancer
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" equal-contrib="yes" id="Au1">
     <name name-style="western">
      <surname>
       Sun
      </surname>
      <given-names>
       Jing
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" equal-contrib="yes" id="Au2">
     <name name-style="western">
      <surname>
       Liu
      </surname>
      <given-names>
       Yue
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Zhao
      </surname>
      <given-names>
       Jianhui
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <name name-style="western">
      <surname>
       Lu
      </surname>
      <given-names>
       Bin
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <name name-style="western">
      <surname>
       Zhou
      </surname>
      <given-names>
       Siyun
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Lu
      </surname>
      <given-names>
       Wei
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <name name-style="western">
      <surname>
       Wei
      </surname>
      <given-names>
       Jingsun
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <name name-style="western">
      <surname>
       Hu
      </surname>
      <given-names>
       Yeting
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <name name-style="western">
      <surname>
       Kong
      </surname>
      <given-names>
       Xiangxing
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <name name-style="western">
      <surname>
       Gao
      </surname>
      <given-names>
       Junshun
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au11">
     <name name-style="western">
      <surname>
       Guan
      </surname>
      <given-names>
       Hong
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au12">
     <name name-style="western">
      <surname>
       Gao
      </surname>
      <given-names>
       Junli
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="author-notes" rid="fn2"/>
    </contrib>
    <contrib contrib-type="author" corresp="yes" id="Au13">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-0120-2371
     </contrib-id>
     <name name-style="western">
      <surname>
       Xiao
      </surname>
      <given-names>
       Qian
      </given-names>
     </name>
     <address>
      <email>
       qxiao3@zju.edu.cn
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="corresp" rid="IDs41467024528942_cor13">
      p
     </xref>
     <xref ref-type="author-notes" rid="fn2"/>
    </contrib>
    <contrib contrib-type="author" id="Au14">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-6880-2577
     </contrib-id>
     <name name-style="western">
      <surname>
       Li
      </surname>
      <given-names>
       Xue
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="author-notes" rid="fn2"/>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/059cjpv64
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.412465.0
      </institution-id>
      <institution content-type="org-division">
       Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education)
      </institution>
      <institution content-type="org-name">
       The Second Affiliated Hospital, Zhejiang University School of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.13402.34
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1759 700X
      </institution-id>
      <institution content-type="org-division">
       Department of Big Data in Health Science, School of Public Health and The Second Affiliated Hospital
      </institution>
      <institution content-type="org-name">
       Zhejiang University School of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.419897.a
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0369 313X
      </institution-id>
      <institution content-type="org-name">
       Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       Zhejiang Provincial Clinical Research Center for CANCER
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00a2xv884
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.13402.34
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1759 700X
      </institution-id>
      <institution content-type="org-name">
       Cancer Center of Zhejiang University
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/059cjpv64
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.412465.0
      </institution-id>
      <institution content-type="org-division">
       Nursing Department
      </institution>
      <institution content-type="org-name">
       The Second Affiliated Hospital of Zhejiang University School of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00a2xv884
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.13402.34
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1759 700X
      </institution-id>
      <institution content-type="org-name">
       Cosmos Wisdom Mass Spectrometry Center of Zhejiang University Medical School
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <fn fn-type="equal" id="fn1">
     <p>
      These authors contributed equally: Jing Sun, Yue Liu.
     </p>
    </fn>
    <fn fn-type="con" id="fn2">
     <p>
      These authors are jointly supervised this work: Junli Gao, Qian Xiao, Xue Li.
     </p>
    </fn>
    <corresp id="IDs41467024528942_cor13">
     <label>
      p
     </label>
     <email>
      qxiao3@zju.edu.cn
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     15
    </day>
    <month>
     10
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="8873">
    1
   </issue>
   <elocation-id>
    8873
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      25
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="received">
     <day>
      21
     </day>
     <month>
      2
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="accepted">
     <day>
      20
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="online">
     <day>
      15
     </day>
     <month>
      10
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
       http://creativecommons.org/licenses/by-nc-nd/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Abstract
    </title>
    <p id="Par1">
     本研究旨在识别与结直肠癌（CRC）相关的蛋白质组学特征，并通过整合蛋白质组学特征与遗传和非遗传因素（QCancer-15）开发CRC发病的预测模型，以改善风险分层并估计个性化初始筛查年龄。采用两阶段策略，我们优先选择了15种蛋白质生物标志物作为预测因子，构建了蛋白质风险评分（ProS）。整合蛋白质组学特征、多基因风险评分（PRS）和QCancer-15风险评分（QCancer-S）的风险预测模型表现出更好的性能（训练队列：C-统计量：0.79 vs. 0.71,
     <italic>
      P
     </italic>
     = 4.94E–03；验证队列：0.75 vs 0.69,
     <italic>
      P
     </italic>
     = 5.49E–04）和净收益，优于单独使用QCancer-S。联合模型显著分层了CRC发病的风险。对于ProS、PRS或联合风险评分高的参与者，建议在46岁、41岁或40岁之前开始筛查。本研究中，血液蛋白质组学与PRS和QCancer-15的整合在风险分层和临床应用方面表现出更好的性能，为CRC筛查的风险适应性起始年龄提供了依据，有助于CRC筛查的决策过程。
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     Non-invasive approaches for risk stratification and screening remain crucial for colorectal cancer (CRC). Here, the authors develop a model for CRC risk stratification by integrating plasma proteomics data with polygenic risk score and QCancer-15 risk score, which could guide recommendations for earlier screening of high-risk populations.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1117">
      Public Health and Health Services
     </kwd>
    </nested-kwd>
   </kwd-group>
   <funding-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        National Natural Science Foundation of China (National Science Foundation of China)
       </institution>
       <institution-id institution-id-type="doi" vocab="open-funder-registry">
        https://doi.org/10.13039/501100001809
       </institution-id>
      </institution-wrap>
     </funding-source>
     <award-id award-type="FundRef grant">
      82072360
     </award-id>
     <award-id award-type="FundRef grant">
      82373234
     </award-id>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Xiao
       </surname>
       <given-names>
        Qian
       </given-names>
      </name>
     </principal-award-recipient>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Xiao
       </surname>
       <given-names>
        Qian
       </given-names>
      </name>
     </principal-award-recipient>
    </award-group>
   </funding-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      8873
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      9
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      25
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2024_Article_52894.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    引言
   </title>
   <p id="Par3">
    结直肠癌（CRC）是全球第三大常见恶性肿瘤，也是第二大癌症死亡原因
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    。目前，减少CRC负担的最有效方法仍然是通过人群筛查进行早期检测。尽管筛查方式因国家而异，但筛查计划主要基于年龄和家族史，未考虑其他风险因素。然而，越来越多的证据表明，CRC风险在人群中的显著差异不仅归因于年龄和家族史，尤其是早发性CRC的发病率近年来逐渐增加
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    。此外，鉴于结肠镜检查（金标准）具有侵入性、耗时且昂贵，进一步识别非侵入性早期筛查和诊断生物标志物，以及开发基于风险的个性化筛查建议以提高筛查效果的需求十分迫切。
   </p>
   <p id="Par4">
    血液蛋白质由于主动分泌或细胞泄漏而出现在循环中，提供了人类健康状态和疾病的全面读数，是生物标志物和治疗靶点的主要来源，具有易于获取和对疾病最内在的预测潜力
    <sup>
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
    </sup>
    。几项研究表明，循环蛋白质与CRC风险之间存在密切联系，并表明蛋白质生物标志物有潜力区分CRC病例和对照组
    <sup>
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
     ,
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    。然而，这些基于蛋白质的预测研究大多基于病例对照设计，样本量较小。基于人群的纵向研究理论上更适合估计与疾病发病相关的早期分子特征，用于风险分层。此外，遗传和已建立的非遗传因素（如QCancer-[15 yr, 结直肠]）也在CRC发病率中发挥重要作用，并有助于CRC的风险分层
    <sup>
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
     ,
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
    </sup>
    。同时利用循环蛋白质、遗传和非遗传因素，有望开发出在CRC中具有更好临床实用性的预测工具。
   </p>
   <p id="Par5">
    在本研究中，我们采用基于病例对照和独立前瞻性人群队列的两阶段策略来识别和验证与CRC相关的蛋白质组学特征（Fig.
    <xref ref-type="fig" rid="Fig1">
     1
    </xref>
    ）。然后，构建QCancer-15风险评分和多基因风险评分（PRSs），并结合关键蛋白质生物标志物，开发CRC发病的预测模型。最后，我们评估了联合模型的预测性能及其在净收益、风险分层和CRC个性化初始筛查年龄方面的潜在临床应用。
    <fig id="Fig1" position="float">
     <label>
      Fig. 1
     </label>
     <caption xml:lang="en">
      <title>
       显示整体研究设计的流程图。
      </title>
      <p>
       BMI 体质指数，TDI Townsend 剥夺指数，PRS 多基因风险评分，RAP 风险提前期。
      </p>
     </caption>
     <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52894-2/41467_2024_52894_Fig1_HTML.png" mime-subtype="PNG" specific-use="web"/>
    </fig>
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    结果
   </title>
   <sec id="Sec3">
    <title>
     结直肠癌的蛋白质组学特征
    </title>
    <p id="Par6">
     在发现阶段，共发现421种CRC病例与对照组之间差异表达的血浆蛋白质，其中243种蛋白质上调（Log2倍变化，Log
     <sub>
      2
     </sub>
     FC &gt; 0，错误发现率，FDR &lt; 0.05）和178种蛋白质下调（Log
     <sub>
      2
     </sub>
     FC &lt; 0，FDR &lt; 0.05）（补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      1
     </xref>
     ）。在验证阶段（英国生物银行，UKBB），中位随访时间为13.05年（四分位数范围，IQR: 12.38–13.75），731名参与者被诊断为CRC（表
     <xref ref-type="table" rid="Tab1">
      1
     </xref>
     ）。421种蛋白质中的253种也在UKBB中测量，共验证了88种。75种蛋白质与新发CRC呈正相关（风险比，HR &gt; 1,
     <italic>
      P
     </italic>
     &lt; 0.05），13种蛋白质与新发CRC呈负相关（HR &lt; 1,
     <italic>
      P
     </italic>
     &lt; 0.05）（补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      1
     </xref>
     ）。
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     风险评分的构建
    </title>
    <p id="Par7">
     在两阶段策略识别的88种蛋白质中，应用最小绝对收缩和选择算子（LASSO）-Cox回归优化与CRC风险相关的蛋白质特征的选择。最终，选择了15种蛋白质生物标志物（IGFBP4, WFDC2, TFF1, LTBP2, COL18A1, CCN3, SELL, PON3, ADGRG2, IGF2R, PZP, CDON, TNXB, APLP1, CR2）构建CRC风险的蛋白质风险评分（ProS）（Fig.
     <xref ref-type="fig" rid="Fig2">
      2
     </xref>
     , 补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ）。UKBB中QCancer-15预测因子的基线特征见表
     <xref ref-type="table" rid="Tab1">
      1
     </xref>
     。构建的ProS（每标准差增量的风险比，HR: 1.24, 95%置信区间[CI]: 1.21–1.28,
     <italic>
      P
     </italic>
     = 1.85 × 10）和QCancer-15风险评分（QCancer-S）（每标准差增量的HR: 1.55, 95% CI: 1.48–1.62,
     <italic>
      P
     </italic>
     = 1.51 × 10）与新发CRC呈正相关（补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ）。使用LDpred2构建了2种PRS。两种PRS均与新发CRC呈正相关，每标准差的PRS对CRC风险的HR分别为1.46（LDpred2-auto）和2.31（LDpred2-grid）（95% CI: 2.15–2.48,
     <italic>
      P
     </italic>
     = 4.36 × 10）（补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ）。
     <fig id="Fig2" position="float">
      <label>
       Fig. 2
      </label>
      <caption xml:lang="en">
       <title>
        用于构建蛋白质风险评分（ProS）的15种血浆蛋白质的结果，这些蛋白质来自全蛋白质组差异表达分析（发现阶段）和Cox比例风险回归分析（验证阶段）。
       </title>
       <p>
        <italic>
         P
        </italic>
        -值是通过双侧检验得出的，并使用错误发现率（FDR）进行多重检验校正。在验证阶段，线的中心代表估计的风险比，线代表95%置信区间。源数据作为源数据文件提供。Log
        <sub>
         2
        </sub>
        FC Log
        <sub>
         2
        </sub>
        倍变化，FDR 错误发现率，HR 风险比，CI 置信区间。
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52894-2/41467_2024_52894_Fig2_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     预测模型的开发与评估
    </title>
    <p id="Par8">
     基于QCancer-S、PRSs和ProS的预测模型分别在UKBB中构建。在训练队列中，QCancer-S和QCancer-S（包括地理区域）的C-统计量均为0.71（95% CI: 0.66, 0.76），无统计学显著差异（
     <italic>
      P
     </italic>
     = 0.63）（Fig.
     <xref ref-type="fig" rid="Fig3">
      3a
     </xref>
     ，补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ）。为了提高通用性，后续建模和分析中使用了QCancer-S。ProS的C-统计量为0.66（95% CI: 0.61, 0.71）（Fig.
     <xref ref-type="fig" rid="Fig3">
      3a
     </xref>
     ）。在2种PRS模型中，LDpred2-grid表现最佳，C-统计量为0.74（95% CI: 0.69, 0.80）（补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ）。然后将表现最佳的PRS（LDpred2-grid）与QCancer-S和ProS结合，构建联合模型，C-统计量达到0.79（95% CI: 0.75, 0.84），在训练队列（C-统计量：0.79 vs. 0.71,
     <italic>
      P
     </italic>
     = 4.94E–03）和验证队列（C-统计量：0.75 vs 0.69,
     <italic>
      P
     </italic>
     = 5.49E–04）中均显著优于单独使用QCancer-S的模型（Fig.
     <xref ref-type="fig" rid="Fig3">
      3a
     </xref>
     ，补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ）。
     <fig id="Fig3" position="float">
      <label>
       Fig. 3
      </label>
      <caption xml:lang="en">
       <title>
        评估基于QCancer-15风险评分（QCancer-S）、多基因风险评分（PRS）、蛋白质风险评分（ProS）和联合模型的结直肠癌（CRC）预测模型。
       </title>
       <p>
        <bold>
         a
        </bold>
        训练队列中QCancer-S、PRS、ProS和联合模型的受试者工作特征（ROC）曲线。
        <bold>
         b
        </bold>
        四个模型在训练队列中预测CRC概率的校准曲线。
        <bold>
         c
        </bold>
        训练队列中QCancer-S和联合模型的决策曲线分析，计算中位随访时间（13.05年）。净收益曲线中的灰色线表示不干预，黑色线表示对所有人进行干预。
        <bold>
         d
        </bold>
        整个人群中5年、10年和15年无CRC的诺模图。源数据作为源数据文件提供。
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52894-2/41467_2024_52894_Fig3_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par9">
     分层分析的结果见补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      3
     </xref>
     。在训练队列中，联合模型的C-统计量为0.76（95% CI: 0.69, 0.83）（女性）和0.77（95% CI: 0.70, 0.84）（男性）。当分别考虑结肠和直肠的CRC风险时，联合模型的C-统计量分别为0.79（95% CI: 0.74, 0.85）（结肠癌）和0.82（95% CI: 0.73, 0.91）（直肠癌）。无论参与者是否曾接受过肠癌筛查或有CRC家族史，联合模型的表现均优于单独使用QCancer-S。联合模型的C-统计量为0.79（95% CI: 0.73, 0.85）（未筛查的参与者），0.79（95% CI: 0.62, 0.95）（在加入UKBB前一年或更早接受过筛查的参与者），0.91（95% CI: 0.85, 0.98）（有家族史的参与者）。验证队列中也观察到了类似的结果。对于无CRC家族史且未筛查的参与者，联合模型在训练队列（C-统计量，0.82 vs. 0.71,
     <italic>
      P
     </italic>
     &lt; 0.05）和验证队列（C-统计量，0.75 vs. 0.71,
     <italic>
      P
     </italic>
     &lt; 0.05）中均表现出更好的区分能力。校准曲线显示，观察率和预测率之间具有良好的一致性（Fig.
     <xref ref-type="fig" rid="Fig3">
      3b
     </xref>
     ，补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     ）。
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     预测模型的净收益
    </title>
    <p id="Par10">
     决策曲线分析显示，联合模型在训练队列、验证队列以及整个人群中，跨多个风险概率范围的净收益均大于单独使用QCancer-S的模型（Fig.
     <xref ref-type="fig" rid="Fig3">
      3c
     </xref>
     ，补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     ）。例如，当风险概率为1%时，联合模型的净收益为0.65%（整个人群），0.62%（训练队列），0.71%（验证队列），这意味着与假设所有参与者均未接受干预相比，每10,000名参与者中，联合模型可以多检测出65例（训练队列62例，验证队列71例）CRC，而不会增加假阳性率和不必要的结肠镜检查。联合模型的净收益比假设所有参与者均接受干预高0.24%（训练队列0.24%，验证队列0.21%），比QCancer-S模型高0.10%（训练队列0.11%，验证队列0.06%）（补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      4
     </xref>
     ）。此外，每100名个体中，联合模型的假阳性率减少了24例（训练队列24例，验证队列21例），而QCancer-S模型的假阳性率减少了14例（训练队列13例，验证队列15例）。在按性别或肿瘤部位分层时，联合模型的表现仍优于单独使用QCancer-S（补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     ）。在无CRC家族史且未筛查的参与者中，联合模型的假阳性率减少了26例，而QCancer-S模型的假阳性率减少了16例（补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     ，补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      4
     </xref>
     ）。
    </p>
   </sec>
   <sec id="Sec7">
    <title>
     不同风险组的结直肠癌风险分层
    </title>
    <p id="Par11">
     <fig id="Fig4" position="float">
      <label>
       Fig. 4
      </label>
      <caption xml:lang="en">
       <title>
        整个人群中不同风险组的结直肠癌（CRC）筛查风险分层和风险适应性起始年龄。
       </title>
       <p>
        基于(
        <bold>
         a
        </bold>
        ) QCancer-S (log-rank
        <italic>
         p
        </italic>
        = 4.13E–54)，(
        <bold>
         b
        </bold>
        ) 多基因风险评分 (PRS) (log-rank
        <italic>
         p
        </italic>
        = 3.98E–79)，(
        <bold>
         c
        </bold>
        ) 蛋白质风险评分 (ProS) (log-rank
        <italic>
         p
        </italic>
        = 5.08E–40)，和 (
        <bold>
         d
        </bold>
        ) 联合风险评分 (ComS) (log-rank
        <italic>
         p
        </italic>
        = 1.82E–121) 的不同风险组的Kaplan–Meier累积发病率曲线。阴影带表示置信区间。基于 (
        <bold>
         e
        </bold>
        ) PRS，(
        <bold>
         f
        </bold>
        ) ProS，和 (
        <bold>
         g
        </bold>
        ) ComS 的不同风险组的年龄特异性10年累积CRC风险。年龄特异性10年累积风险曲线中的虚线表示一般人群中50岁（当前指南推荐的平均风险成人筛查起始年龄）的风险。源数据作为源数据文件提供。
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52894-2/41467_2024_52894_Fig4_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec8">
    <title>
     不同分层组的结直肠癌风险提前期
    </title>
    <p id="Par12"/>
   </sec>
   <sec id="Sec9">
    <title>
     结直肠癌筛查的风险适应性起始年龄
    </title>
    <p id="Par13">
     随后计算了10年累计风险，以估计不同风险组整个人群的个性化初始筛查年龄。低、中、高PRS的参与者达到与普通人群50岁平均风险相等的10年累计CRC风险的年龄分别为&gt;60岁、53岁和41岁（Fig.
     <xref ref-type="fig" rid="Fig4">
      4e
     </xref>
     , 表
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ）。低、中、高ProS的参与者达到与普通人群50岁平均风险相等的10年累计CRC风险的年龄分别为57岁、47岁和46岁（Fig.
     <xref ref-type="fig" rid="Fig4">
      4f
     </xref>
     , 表
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ）。当整合ProS、PRS和QCancer-S时，低、中、高ComS的参与者达到与普通人群50岁平均风险相等的10年累计CRC风险的年龄分别为&gt;60岁、48岁和
    </p>
   </sec>
  </sec>
  <sec id="Sec10" sec-type="discussion">
   <title>
    讨论
   </title>
   <p id="Par14">
    采用两阶段策略，我们识别了与CRC相关的循环蛋白质组学特征，并优先选择了15种蛋白质生物标志物用于风险分层。整合蛋白质组学特征与遗传（即PRS）和非遗传因素（即QCancer-15）的预测模型在所有指标上均优于单独使用QCancer-15。此外，联合模型显著分层了CRC发病的风险，并推导了CRC筛查的风险适应性起始年龄。与中等风险组相比，高ProS、PRS或ComS的参与者达到等效CRC风险的时间分别提前了4.7年、17.9年或甚至27.5年，而低ProS、PRS或ComS组的参与者则分别晚了4.4年、8.9年或15.2年。以50岁普通人群为参考，高ProS、PRS或ComS的参与者建议在46岁、41岁或40岁之前开始筛查，而相应的低分组的参与者建议在57岁或60岁之后开始筛查。在无CRC家族史且未筛查的参与者中也观察到了类似的结果。
   </p>
   <p id="Par15">
    两阶段研究设计识别并优先选择了15种与CRC发病相关的循环蛋白质生物标志物。其中大多数已报告与CRC风险、预后或治疗反应在蛋白质水平（如TFF1、LTBP2、PZP）、mRNA表达（如TFF1、LTBP2、WFDC2、CDON）、DNA甲基化（如PON3）或基因多态性（如CR2）有关
    <sup>
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     ,
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ,
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     ,
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
    </sup>
    。TFF1（Trefoil factor 1）属于Trefoil家族成员，这些成员是表达在胃肠道黏膜中的稳定分泌蛋白。与我们的发现一致，先前的研究报告称，CRC患者的血清TFF1水平显著高于健康对照组，TFF1的mRNA水平在CRC组织中高于相邻正常组织，并通过激活上皮-间质转化过程促进了结肠癌的恶性行为
    <sup>
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
    </sup>
    。LTBP2（Latent-transforming growth factor beta-binding protein 2）是Fibrillin/LTBP超家族的成员。据报道，CRC组织中的LTBP2 mRNA和蛋白质水平显著高于相邻正常组织，高LTBP2蛋白质水平与CRC患者的总体生存率较差有关，表明LTBP2可能在CRC发展中起致癌基因作用，并是预测CRC预后的关键生物标志物
    <sup>
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
    </sup>
    。我们还指出，血浆PZP（Pregnancy zone protein）对CRC发病风险具有保护作用。同样，Wang等人报告称，血清PZP蛋白质水平与新辅助放化疗（nCRT）的反应有关，PZP水平较高的直肠癌患者倾向于病理完全缓解，对直肠癌的nCRT具有潜在的预测价值
    <sup>
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
    </sup>
    。
   </p>
   <p id="Par16">
    基于个体化风险预测的主动方法被描述为癌症早期检测的未来，强调了流行病学因素、遗传变异和组学生物标志物（特别是蛋白质生物标志物）的多因素癌症风险评估
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
    </sup>
    。先前的研究基于仅PRS或非遗传预测因子或两者结合开发了CRC风险预测模型，并观察到整合PRS和非遗传预测因子的模型表现优于单独使用非遗传预测因子或PRS
    <sup>
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
    </sup>
    。具体而言，我们基于116个GWAS显著SNPs的先前研究产生了0.6的C-统计量
    <sup>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
    </sup>
    。Thomas等人报告了基于非西班牙裔白人的跨祖先PRS单独模型的CRC风险C-统计量为0.65
    <sup>
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
    </sup>
    。Briggs等人整合了QCancer和PRS，产生了男性预测CRC风险的C-统计量为0.73，女性为0.69，另一项研究在结合PRS和非遗传预测因子后报告了0.72的C-统计量
    <sup>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
    </sup>
    。此外，一项基于美国人群的病例对照研究在将先前研究基于候选策略报告的11种血浆生物标志物添加到非遗传风险因素模型后，显示了改进的区分能力，C-统计量为0.66–0.73
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    。一致地，我们的工作支持并扩展了这些发现。尽管在蛋白质覆盖范围（候选策略与蛋白质组）、研究设计和研究人群方面存在差异，但他们的模型中包含的蛋白质（IGFBP3）和我们模型中包含的蛋白质（IGFBP4）都属于胰岛素样生长因子结合蛋白家族，这在一定程度上表明了其通用性。通过整合蛋白质组学特征与PRS和QCancer-15，我们构建了一个C-统计量为0.79的联合模型，用于预测前瞻性队列中CRC发病的风险，其表现优于训练队列和验证队列中的QCancer-15或PRS单独模型。此外，决策曲线分析和Kaplan–Meier曲线的结果显示，联合模型相对于单独使用QCancer-15模型的净收益增加，并提示了CRC风险分层的潜在临床应用。
   </p>
   <p id="Par17"/>
   <p id="Par18">
    本研究具有一些优势。首先，基于高通量蛋白质组学技术的两阶段设计用于识别与CRC相关的蛋白质组学特征，这确保了在不同人群和蛋白质组学平台中与CRC具有稳定关联的蛋白质用于建模，提高了这些发现的普遍性。其次，基于社区的前瞻性队列具有较大的样本量、良好的代表性以及长期随访，使我们能够建立基于人群的CRC发病预测模型。第三，将循环蛋白质组学特征与遗传和已建立的非遗传因素相结合，提供了人类健康状态的全面读数，有助于更精确和全面的CRC风险分层，以帮助将有限的资源集中在高风险个体上。第四，RAP和10年累计风险为CRC筛查的风险适应性起始年龄提供了相似的结果，这表明当前发现的稳定性和可靠性。此外，构建模型所需的参数可以从自我报告和单一非侵入性生物样本（即血液）中获得，这确保了模型的可行性和接受度。然而，本研究的几个局限性需要仔细考虑。首先，尽管通过基于中国和UKBB人群的两阶段设计识别了与CRC相关的蛋白质组学生物标志物，但预测模型仅在UKBB（包括欧洲和非欧洲血统的参与者）中建立，并且只有内部验证。在常规护理中应用当前发现之前，需要基于独立外部人群的进一步研究来评估其普遍性。其次，由于QCancer-S中包含并主导了年龄信息，RAP和10年累计风险不能用于评估不同QCancer-S组的CRC筛查的风险适应性起始年龄。进一步研究评估已建立的非遗传因素（不包括年龄）在CRC筛查的风险适应性起始年龄中的贡献可能很有趣。此外，尽管大多数RAP估计值在训练队列和验证队列之间相似，但验证队列中某些风险评分组的RAP估计值不显著，这可能部分归因于病例数量较少。最后，筛查策略不仅包括初始筛查年龄，还包括筛查间隔。未来研究需要调查风险适应性CRC筛查的筛查间隔。
   </p>
   <p id="Par19">
    总之，血液蛋白质组学与PRS和QCancer-15的整合在风险分层和临床应用方面表现出更好的性能，为CRC筛查的风险适应性起始年龄提供了依据。这可能有助于CRC筛查的决策过程，具有减少低风险人群筛查负担的潜力，同时提高筛查检出率。未来研究需要评估联合模型和风险适应性筛查年龄的接受度、可行性和成本效益。
   </p>
  </sec>
  <sec id="Sec11" sec-type="methods">
   <title>
    方法
   </title>
   <sec id="Sec12">
    <title>
     伦理批准和参与同意
    </title>
    <p id="Par20">
     本研究的发现阶段获得了浙江大学医学院第二附属医院伦理委员会的伦理批准（2023-1190）。UKBB获得了西北多中心研究伦理委员会的批准（11/NW/0382）。所有参与者均提供了书面知情同意，本研究遵循赫尔辛基宣言。
    </p>
   </sec>
   <sec id="Sec13">
    <title>
     研究设计和参与者
    </title>
    <p id="Par21">
     流程图显示了整体研究设计（Fig.
     <xref ref-type="fig" rid="Fig1">
      1
     </xref>
     ）。简而言之，采用两阶段策略，我们首先通过基于病例对照设计的全蛋白质组差异表达分析探索了与CRC相关的蛋白质生物标志物，并在独立的前瞻性人群队列中进行了验证。然后，构建了ProS、QCancer-S和PRSs，并将其整合以开发基于前瞻性人群队列的CRC发病预测模型。最后，评估了联合模型的预测性能和潜在临床应用（例如，净收益、风险分层和个性化初始筛查年龄）。
    </p>
    <p id="Par22">
     发现阶段包括150例新诊断的CRC病例（年龄范围：44-89岁）和50例性别和年龄匹配的对照组，来自浙江大学医学院第二附属医院。验证队列包括2006年至2010年招募的UKBB中的CRC新发病例和对照组。选择了具有蛋白质组学测量的参与者。排除了在招募时患有CRC和缺失基因型数据的个体后，UKBB中剩余52,231名个体（731例CRC新发病例，51,500名对照组），年龄在39-70岁之间。
    </p>
   </sec>
   <sec id="Sec14">
    <title>
     结果定义
    </title>
    <p id="Par23">
     主要结局是CRC诊断，定义为结直肠恶性肿瘤，由发现队列中的临床医生和病理学家诊断，或通过与医院数据和癌症及死亡登记处的链接，使用国际疾病分类（ICD，ICD-9: 153, 154.0, 154.1；或ICD-10: C18-C20）在UKBB中诊断。参与者加入UKBB的日期被视为随访期的开始，随访在CRC发病、死亡、失访或可用登记随访结束（2021年3月31日）中最早发生的时间被截断。
    </p>
   </sec>
   <sec id="Sec15">
    <title>
     血浆蛋白质组学测量
    </title>
    <p id="Par24">
     在参与者入组时收集了血液样本，并制备了血浆样本，储存在–80 °C。使用碘化串联质谱标签（TMT）-6plex定量蛋白质组学在发现队列中生成蛋白质测量值。肽段的定量是通过CRC样本通道与对照组通道的比例进行的，并通过Log
     <sub>
      2
     </sub>
     转换和分位数方法进行归一化。蛋白质组测量、处理和质量控制（QC）的详细信息在补充方法中描述。经过QC后，共鉴定出606种蛋白质，并纳入后续分析（补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      8
     </xref>
     ）。
    </p>
    <p id="Par25">
     在UKBB中，样本选择、蛋白质组测量、处理和QC的详细信息已在其他地方描述
     <sup>
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
     </sup>
     。简而言之，使用Olink邻近延伸测定法量化了2923种蛋白质的相对丰度，测量值通过Log
     <sub>
      2
     </sub>
     转换表示为归一化的蛋白质表达值。低于检测限（LOD）的蛋白质值通过将LOD除以2的平方根进行替换。缺失的蛋白质测量值通过均值进行填补。对于在发现阶段CRC病例和对照组之间差异表达的蛋白质，我们进一步基于UKBB的前瞻性队列设计验证了它们与CRC风险的关系。
    </p>
   </sec>
   <sec id="Sec16">
    <title>
     统计分析
    </title>
    <sec id="Sec17">
     <title>
      基线特征描述
     </title>
     <p id="Par26">
      使用Kolmogorov–Smirnov正态性检验来识别连续变量的分布类型。中位数（IQR）用于描述连续变量，数量（百分比）用于描述分类变量。
     </p>
    </sec>
   </sec>
   <sec id="Sec18">
    <title>
     结直肠癌相关蛋白质生物标志物的识别
    </title>
    <p id="Par27">
     采用两阶段策略来识别与CRC相关的蛋白质组特征。在基于病例对照设计的发现阶段，使用主成分分析和Pearson相关系数矩阵来识别异常样本（补充方法），并识别出20个定量异常的样本（补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      8
     </xref>
     ）。在去除异常样本后，基于‘limma’包进行了全蛋白质组差异表达分析，以识别CRC病例和对照组之间上调（Log
     <sub>
      2
     </sub>
     FC &gt; 0）或下调（Log
     <sub>
      2
     </sub>
     FC &lt; 0）的蛋白质。使用FDR进行多重检验校正，FDR &lt; 0.05作为显著性水平。对于发现阶段中显著的蛋白质（FDR &lt; 0.05），我们进一步使用Cox比例风险（CPH）模型评估了它们与验证队列中CRC发病率的关系。在验证阶段中具有一致效应方向和显著
     <italic>
      P
     </italic>
     -值（
     <italic>
      P
     </italic>
     &lt; 0.05）的蛋白质被认为是成功的验证
     <sup>
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
     </sup>
     。
    </p>
   </sec>
   <sec id="Sec19">
    <title>
     QCancer-15的定义
    </title>
    <p id="Par28">
     QCancer-15 预测因子的编码基于 UKBB 的基线特征，尽可能接近原始模型
     <sup>
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
     </sup>
     。QCancer-15 预测因子包括年龄（招募时的年龄）、性别、Townsend 剥夺指数、地理区域、体重指数（BMI）、吸烟状况、酒精摄入、CRC 家族史和既往病史。这些变量中缺失数据的个体被分配到每个相应变量的“缺失”类别。这些预测因子的编码细节见补充数据
     <xref ref-type="supplementary-material" rid="MOESM4">
      9
     </xref>
     <sup/>
     。为了在其他人群中具有通用性，我们从 QCancer-15 预测因子中排除了针对英国人口定制的地理区域变量。
    </p>
   </sec>
   <sec id="Sec20">
    <title>
     多基因风险评分（PRS）的推导方法
    </title>
    <p id="Par29">
     迄今为止，最大的跨种族 CRC 全基因组关联研究（GWAS）包括欧洲血统（21,731 例和 47,444 例对照，东亚血统；78,473 例和 107,143 例对照，欧洲血统）被用于提供每个单核苷酸多态性（SNP）的关联效应大小。使用 LDpred2 构建全基因组 PRS，该方法基于贝叶斯方法并考虑了 SNP 之间的连锁不平衡（LD）
     <sup>
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
     </sup>
     。执行了两种不同的 LDpred2 模型，包括自动模型（LDpred2-auto）和网格模型（LDpred2-grid），使用 HapMap3+ 数据集作为参考。共开发了 2 种 PRS。详细内容见补充方法。
    </p>
   </sec>
   <sec id="Sec21">
    <title>
     风险评分的构建和预测模型的开发
    </title>
    <p id="Par30">
     通过 LASSO-Cox 回归在通过两阶段测试的蛋白质中进一步选择了与 CRC 相关的蛋白质特征，共选择了 15 种蛋白质。基于 UKBB 中选择的 15 种蛋白质或 QCancer-15 预测因子，分别使用 R 包 ‘caret’（版本 6.0.94）的 ‘predict’ 函数构建了加权 ProS 或 QCancer-S（风险评分 = h0(t) * exp(β1×1 + β2×2 + … + βnXn)）。其中 Xn 是蛋白质（或 QCancer-15 预测因子）的水平，βn 是从 CPH 模型中得出的与 CRC 风险相关的蛋白质（或 QCancer-15 预测因子）的系数，h0(t) 是基线风险。详细内容见补充方法。然后，使用 ‘caret’ 包将 UKBB 参与者随机分为训练队列和验证队列，比例为 7:3。基于 QCancer-S、QCancer-S（包括地理区域）、2 种 PRS 或 ProS，分别使用训练队列中的五折交叉验证 CPH 模型开发了 CRC 风险预测模型。接下来，将表现最佳的 QCancer-S、ProS 和 PRS 结合，构建了联合模型，用于预测 CRC 发病的风险。这些模型还通过性别、肿瘤部位（结肠或直肠）、肠癌筛查（是或否）和 CRC 家族史（是或否）进行了分层评估
     <sup>
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
     </sup>
     。
    </p>
   </sec>
   <sec id="Sec22">
    <title>
     模型性能评估和潜在临床应用
    </title>
    <p id="Par31">
     使用广泛的指标评估了模型的性能，包括受试者工作特征曲线下的面积（AUC，即 C-统计量）、相对风险校准、净收益、风险比估计、风险分层、风险提前期和 10 年累计 CRC 发病风险。
    </p>
   </sec>
   <sec id="Sec23">
    <title>
     模型的区分度和校准
    </title>
    <p id="Par32">
     通过五折交叉验证在训练队列中评估了这些模型的 C-统计量（95% 置信区间，CI），并在验证队列中进一步评估。使用 bootstrap 方法比较了不同模型性能的差异，进行了 500 次分层 bootstrap 重复。使用 ‘riskRegression’ 包绘制了校准曲线，以直观地展示基于 CPH 模型的观察事件率和预测风险之间的吻合度。为预测 5 年、10 年和 15 年无 CRC 的风险，建立了 QCancer-S、PRS 和 ProS 的列线图
     <sup>
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
     </sup>
     。
    </p>
   </sec>
   <sec id="Sec24">
    <title>
     决策曲线分析
    </title>
    <p id="Par33">
     为了评估预测模型在推荐CRC干预措施（例如筛查）方面的潜在临床效用，使用‘ggDCA’包进行了决策曲线分析，以计算使用QCancer-S单独或联合模型（QCancer-S + PRS + ProS）选择个体进行筛查结肠镜检查所获得的净收益（NB）。NB = ((真阳性)/
     <italic>
      n
     </italic>
     ) – ((假阳性)/
     <italic>
      n
     </italic>
     ) ∗ (
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     /(1−
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     ))，其中
     <italic>
      n
     </italic>
     是总人数，
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     是风险（或概率）阈值（例如，在
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     = 1%时，愿意为100名参与者进行结肠镜检查以检测1例CRC病例）
     <sup>
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
     </sup>
     。我们将联合模型与基于QCancer-S单独的模型以及不干预和全部干预进行了比较。每100人中假阳性数量的减少通过以下公式估计：100*(模型的NB–全部干预的NB)/(
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     /(1–
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     ))。在中位随访时间（13.05年）内，不同风险阈值下的NB值绘制在决策曲线上。报告了在一系列预设风险阈值（1%，1.5%，2%，2.5%，和3%）下的NB值。
    </p>
   </sec>
   <sec id="Sec25">
    <title>
     风险比估计和风险分层分析
    </title>
    <p id="Par34">
     HRs首先从CPH回归中得出，用于QCancer-S、PRS和ProS每标准差增加对总体、性别特异性和部位特异性CRC风险的影响。然后，根据当前UKBB人群中的分布，将QCancer-S、PRS、ProS和ComS（补充方法）分别分为四分位数（Q1-最低，Q2，Q3，和Q4-最高）。由于10年累积风险曲线的趋势相似，风险评分进一步分为3组（低、中、高）（补充图.
     <xref ref-type="supplementary-material" rid="MOESM1">
      9
     </xref>
     ）。具体来说，以一般人群的10年累积风险为参考，Q3组中风险与一般人群相似的参与者被归类为中风险组，Q1和Q2组中风险低于一般人群的参与者被归类为低风险组，Q4组中的参与者被归类为高风险组。还使用中等组作为参考，估计了分类变量的HRs（95%置信区间）。通过Kaplan–Meier曲线和对数秩检验评估了风险评分的风险分层价值。
    </p>
   </sec>
   <sec id="Sec26">
    <title>
     风险提前期（RAP）分析
    </title>
    <p id="Par35">
     为了将PRS、ProS和ComS的HRs转化为低或高PRS、ProS和ComS组的个体达到与参考组（即中等PRS、ProS或ComS水平的个体）相当的风险所需提前或推迟的年数，进行了RAP分析。由于QCancer-S本身包含了年龄信息并占据主导地位，因此未通过RAP评估QCancer-S。RAP的点估计值通过多变量CPH模型得出，该模型包括年龄、PRS（低、中、高）和ProS（低、中、高），以及性别和前10个遗传主成分（PCs）作为协变量，通过将PRS或ProS的回归系数除以年龄的回归系数来估计。在估计ComS的RAP时，模型包括年龄、ComS（低、中、高）、性别和前10个PCs，其中RAP通过将ComS的回归系数除以年龄的回归系数来估计。RAP的95%置信区间基于bootstrap方法计算，使用500个分层bootstrap重复
     <sup>
      <xref ref-type="bibr" rid="CR35">
       35
      </xref>
     </sup>
     。
    </p>
   </sec>
   <sec id="Sec27">
    <title>
     估计筛查的风险适应性起始年龄
    </title>
    <p id="Par36">
     为了进一步估计不同风险组人群的风险适应性筛查起始年龄，计算了10年累积风险。考虑到整个UKBB人群更具信息性和代表性，我们基于整个人群估计了风险适应性筛查起始年龄。10年累积风险 = 1–exp(–10年累积发病率)，其中10年累积发病率等于每个年龄的每个后续10年年龄特异性年发病率之和
     <sup>
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
     </sup>
     。年龄特异性年发病率通过将每个年龄的病例数除以该年龄的人年数来计算。鉴于当前指南建议平均风险成年人的筛查起始年龄为50岁，我们将风险适应性筛查起始年龄定义为具有特定CRC风险的个体达到与50岁一般人群相似的10年累积风险的年龄
     <sup>
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
     </sup>
     。所有统计检验均为双侧检验，并使用R 4.2.2版本进行。
    </p>
   </sec>
   <sec id="Sec28">
    <title>
     报告摘要
    </title>
    <p id="Par37">
     有关研究设计的进一步信息可在链接到本文的
     <xref ref-type="supplementary-material" rid="MOESM5">
      Nature Portfolio Reporting Summary
     </xref>
     中获得。
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Acknowledgements
   </title>
   <p>
    作者感谢来自浙江大学医学院第二附属医院和英国生物银行的所有参与者，以及提供数据的机构及其工作人员。Q.X. 得到国家自然科学基金（No. 82072360, 82373234）和浙江省卫生健康委员会区域诊疗中心项目（No. JBZX-201903）的支持。X.L. 得到浙江省自然科学基金杰出青年基金（LR22H260001）、国家自然科学基金（82204019）和浙江省癌症临床研究中心（2022E50008, 2024ZY01056）的支持。Y.H. 得到浙江省癌症临床研究中心（2022E50008.2024ZY01056）和浙江省重点研发计划（2023C03049）的支持。资助方在研究设计、数据收集和分析、决定发表或准备手稿方面没有作用。
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Author contributions
   </title>
   <p>
    这些作者是共同通讯作者：Xue Li, Qian Xiao, Junli Gao. X.L., Q.X., J.-L.G., 和 J.S. 贡献于研究概念和设计。材料准备、数据收集、方法学、正式分析和可视化由 J.S., Y.L., J.Z., B.L., 和 S.Z. 完成。H.G., J.-S.G., W.L., J.W., Y.-T.H., 和 X.K. 贡献于项目管理。手稿的初稿由 J.S., X.L., Q.X., J-L.G. 撰写，所有其他作者对先前版本的手稿进行了修订和评论。X.L. 是研究的担保人，并证明所有列出的作者均符合作者资格标准，且没有遗漏其他符合标准的作者。所有作者阅读并批准了最终手稿。
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    同行评审
   </title>
   <sec id="FPar1">
    <title>
     同行评审信息
    </title>
    <p id="Par38">
     <italic>
      Nature Communications
     </italic>
     thanks Jun Zhong and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec sec-type="data-availability">
   <title>
    数据可用性
   </title>
   <p>
    The raw data of plasma proteomics generated in this study have been deposited in the iProX database under accession code IPX0008947000 (the equivalent ProteomeXChange PXD code: PXD054569) and
    <ext-link ext-link-type="uri" xlink:href="https://www.iprox.cn//page/subproject.html?id=IPX0008947001">
     IPX0008947001
    </ext-link>
    . The UK Biobank data are available under restricted access for data protocol, access can be obtained by registering and applying at
    <ext-link ext-link-type="uri" xlink:href="http://ukbiobank.ac.uk/register-apply/">
     http://ukbiobank.ac.uk/register-apply/
    </ext-link>
    . This study used the UK Biobank data under application number 66354. The result data generated in this study are provided in the Supplementary Information/Source Data file. The CRC GWAS summary statistics
    <sup>
     <xref ref-type="bibr" rid="CR30">
      30
     </xref>
    </sup>
    are available through the GWAS catalog (accession no. GCST90129505).
    <xref ref-type="sec" rid="Sec30">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    代码可用性
   </title>
   <p>
    Analysis code is available at
    <ext-link ext-link-type="uri" xlink:href="https://github.com/shuaidexue/Proteomics-predicted-colorectal-cancer-risk">
     https://github.com/shuaidexue/Proteomics-predicted-colorectal-cancer-risk
    </ext-link>
    .
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     竞争利益
    </title>
    <p id="Par39">
     The authors declare no competing interests.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    参考文献
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sung
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
      </article-title>
      <source>
       CA Cancer J. Clin.
      </source>
      <year>
       2021
      </year>
      <volume>
       71
      </volume>
      <fpage>
       209
      </fpage>
      <lpage>
       249
      </lpage>
      <pub-id pub-id-type="doi">
       10.3322/caac.21660
      </pub-id>
      <pub-id pub-id-type="pmid">
       33538338
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sinicrope
        </surname>
        <given-names>
         FA
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Increasing incidence of early-onset colorectal cancer
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2022
      </year>
      <volume>
       386
      </volume>
      <fpage>
       1547
      </fpage>
      <lpage>
       1558
      </lpage>
      <pub-id pub-id-type="doi">
       10.1056/NEJMra2200869
      </pub-id>
      <pub-id pub-id-type="pmid">
       35443109
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtFGrsLnM
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Anderson
        </surname>
        <given-names>
         NL
        </given-names>
       </name>
       <name>
        <surname>
         Anderson
        </surname>
        <given-names>
         NG
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The human plasma proteome: history, character, and diagnostic prospects
      </article-title>
      <source>
       Mol. Cell Proteom.
      </source>
      <year>
       2002
      </year>
      <volume>
       1
      </volume>
      <fpage>
       845
      </fpage>
      <lpage>
       867
      </lpage>
      <pub-id pub-id-type="doi">
       10.1074/mcp.R200007-MCP200
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD3sXht1Ciug%3D%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Suhre
        </surname>
        <given-names>
         K
        </given-names>
       </name>
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         MI
        </given-names>
       </name>
       <name>
        <surname>
         Schwenk
        </surname>
        <given-names>
         JM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Genetics meets proteomics: perspectives for large population-based studies
      </article-title>
      <source>
       Nat. Rev. Genet.
      </source>
      <year>
       2021
      </year>
      <volume>
       22
      </volume>
      <fpage>
       19
      </fpage>
      <lpage>
       37
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41576-020-0268-2
      </pub-id>
      <pub-id pub-id-type="pmid">
       32860016
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhslSltLnL
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome
      </article-title>
      <source>
       Genome Med.
      </source>
      <year>
       2023
      </year>
      <volume>
       15
      </volume>
      <pub-id pub-id-type="doi">
       10.1186/s13073-023-01229-9
      </pub-id>
      <pub-id pub-id-type="pmid">
       37726845
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10508028
      </pub-id>
      <elocation-id>
       75
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Prospective
      </article-title>
      <source>
       Cancers
      </source>
      <year>
       2022
      </year>
      <volume>
       14
      </volume>
      <fpage>
       3261
      </fpage>
      <pub-id pub-id-type="doi">
       10.3390/cancers14133261
      </pub-id>
      <pub-id pub-id-type="pmid">
       35805033
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9265260
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhvVCltrrP
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ahn
        </surname>
        <given-names>
         SB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel
      </article-title>
      <source>
       Clin. Proteom.
      </source>
      <year>
       2019
      </year>
      <volume>
       16
      </volume>
      <fpage>
       34
      </fpage>
      <pub-id pub-id-type="doi">
       10.1186/s12014-019-9255-z
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Harlid
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A two-tiered targeted proteomics approach to identify pre-diagnostic biomarkers of colorectal cancer risk
      </article-title>
      <source>
       Sci. Rep.
      </source>
      <year>
       2021
      </year>
      <volume>
       11
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021NatSR..11.5151H
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41598-021-83968-6
      </pub-id>
      <pub-id pub-id-type="pmid">
       33664295
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7933352
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXlvF2htbw%3D
      </pub-id>
      <elocation-id>
       5151
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fang
        </surname>
        <given-names>
         Z
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Risk prediction models for colorectal cancer: evaluating the discrimination due to added biomarkers
      </article-title>
      <source>
       Int. J. Cancer
      </source>
      <year>
       2021
      </year>
      <volume>
       149
      </volume>
      <fpage>
       1021
      </fpage>
      <lpage>
       1030
      </lpage>
      <pub-id pub-id-type="doi">
       10.1002/ijc.33621
      </pub-id>
      <pub-id pub-id-type="pmid">
       33948940
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhtFGksL7E
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Usher-Smith
        </surname>
        <given-names>
         JA
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       External validation of risk prediction models for incident colorectal cancer using UK Biobank
      </article-title>
      <source>
       Br. J. Cancer
      </source>
      <year>
       2018
      </year>
      <volume>
       118
      </volume>
      <fpage>
       750
      </fpage>
      <lpage>
       759
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/bjc.2017.463
      </pub-id>
      <pub-id pub-id-type="pmid">
       29381683
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5846069
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC1MvlsVOhsQ%3D%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hippisley-Cox
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Coupland
        </surname>
        <given-names>
         C
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study
      </article-title>
      <source>
       BMJ Open
      </source>
      <year>
       2015
      </year>
      <volume>
       5
      </volume>
      <fpage>
       e007825
      </fpage>
      <pub-id pub-id-type="doi">
       10.1136/bmjopen-2015-007825
      </pub-id>
      <pub-id pub-id-type="pmid">
       25783428
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4368998
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Briggs
        </surname>
        <given-names>
         SEW
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort study
      </article-title>
      <source>
       BMJ
      </source>
      <year>
       2022
      </year>
      <volume>
       379
      </volume>
      <fpage>
       e071707
      </fpage>
      <pub-id pub-id-type="doi">
       10.1136/bmj-2022-071707
      </pub-id>
      <pub-id pub-id-type="pmid">
       36351667
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9644277
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Vocka
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer
      </article-title>
      <source>
       Neoplasma
      </source>
      <year>
       2015
      </year>
      <volume>
       62
      </volume>
      <fpage>
       470
      </fpage>
      <lpage>
       477
      </lpage>
      <pub-id pub-id-type="doi">
       10.4149/neo_2015_056
      </pub-id>
      <pub-id pub-id-type="pmid">
       25866228
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC28Xlt12hsbs%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Huang
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       High expression of LTBP2 contributes to poor prognosis in colorectal cancer patients and correlates with the mesenchymal colorectal cancer subtype
      </article-title>
      <source>
       Dis. Mark.
      </source>
      <year>
       2019
      </year>
      <volume>
       2019
      </volume>
      <elocation-id>
       5231269
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wang
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Predictive value of proteomic markers for advanced rectal cancer with neoadjuvant chemoradiotherapy
      </article-title>
      <source>
       BMC Cancer
      </source>
      <year>
       2022
      </year>
      <volume>
       22
      </volume>
      <pub-id pub-id-type="doi">
       10.1186/s12885-022-09960-z
      </pub-id>
      <pub-id pub-id-type="pmid">
       35945555
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9361520
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xit1Cls7zI
      </pub-id>
      <elocation-id>
       868
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Yusufu
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       TFF3 and TFF1 expression levels are elevated in colorectal cancer and promote the malignant behavior of colon cancer by activating the EMT process
      </article-title>
      <source>
       Int. J. Oncol.
      </source>
      <year>
       2019
      </year>
      <volume>
       55
      </volume>
      <fpage>
       789
      </fpage>
      <lpage>
       804
      </lpage>
      <pub-id pub-id-type="pmid">
       31432157
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6741840
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVCgsLs%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Shi
        </surname>
        <given-names>
         LP
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       MicroRNA-149 sensitizes colorectal cancer to radiotherapy by downregulating human epididymis protein 4
      </article-title>
      <source>
       Am. J. Cancer Res
      </source>
      <year>
       2018
      </year>
      <volume>
       8
      </volume>
      <fpage>
       30
      </fpage>
      <lpage>
       38
      </lpage>
      <pub-id pub-id-type="pmid">
       29416918
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5794719
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXntlyitro%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Delloye-Bourgeois
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Sonic Hedgehog promotes tumor cell survival by inhibiting CDON pro-apoptotic activity
      </article-title>
      <source>
       PLoS Biol.
      </source>
      <year>
       2013
      </year>
      <volume>
       11
      </volume>
      <fpage>
       e1001623
      </fpage>
      <pub-id pub-id-type="doi">
       10.1371/journal.pbio.1001623
      </pub-id>
      <pub-id pub-id-type="pmid">
       23940460
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3735457
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Baharudin
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Identification of predictive DNA methylation biomarkers for chemotherapy response in colorectal cancer
      </article-title>
      <source>
       Front Pharm.
      </source>
      <year>
       2017
      </year>
      <volume>
       8
      </volume>
      <fpage>
       47
      </fpage>
      <pub-id pub-id-type="doi">
       10.3389/fphar.2017.00047
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zhao
        </surname>
        <given-names>
         Q
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2022
      </year>
      <volume>
       13
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2022NatCo..13.2342Z
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-022-30062-8
      </pub-id>
      <pub-id pub-id-type="pmid">
       35487942
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9055073
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtFOhsb%2FE
      </pub-id>
      <elocation-id>
       2342
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fitzgerald
        </surname>
        <given-names>
         RC
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The future of early cancer detection
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2022
      </year>
      <volume>
       28
      </volume>
      <fpage>
       666
      </fpage>
      <lpage>
       677
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41591-022-01746-x
      </pub-id>
      <pub-id pub-id-type="pmid">
       35440720
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtVGrsLbE
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Thomas
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2023
      </year>
      <volume>
       14
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2023NatCo..14.6147T
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-023-41819-0
      </pub-id>
      <pub-id pub-id-type="pmid">
       37783704
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10545678
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXitVKlsbzE
      </pub-id>
      <elocation-id>
       6147
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Li
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Prediction of colorectal cancer risk based on profiling with common genetic variants
      </article-title>
      <source>
       Int. J. Cancer
      </source>
      <year>
       2020
      </year>
      <volume>
       147
      </volume>
      <fpage>
       3431
      </fpage>
      <lpage>
       3437
      </lpage>
      <pub-id pub-id-type="doi">
       10.1002/ijc.33191
      </pub-id>
      <pub-id pub-id-type="pmid">
       32638365
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVSrsLnM
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kachuri
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2020
      </year>
      <volume>
       11
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2020NatCo..11.6084K
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-020-19600-4
      </pub-id>
      <pub-id pub-id-type="pmid">
       33247094
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7695829
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXisFShtbjO
      </pub-id>
      <elocation-id>
       6084
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Tian
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Calculating the starting age for screening in relatives of patients with colorectal cancer based on data from large nationwide data sets
      </article-title>
      <source>
       Gastroenterology
      </source>
      <year>
       2020
      </year>
      <volume>
       159
      </volume>
      <fpage>
       159
      </fpage>
      <lpage>
       168.e3
      </lpage>
      <pub-id pub-id-type="doi">
       10.1053/j.gastro.2020.03.063
      </pub-id>
      <pub-id pub-id-type="pmid">
       32251666
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chen
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Personalized initial screening age for colorectal cancer in individuals at average risk
      </article-title>
      <source>
       JAMA Netw. Open
      </source>
      <year>
       2023
      </year>
      <volume>
       6
      </volume>
      <fpage>
       e2339670
      </fpage>
      <pub-id pub-id-type="doi">
       10.1001/jamanetworkopen.2023.39670
      </pub-id>
      <pub-id pub-id-type="pmid">
       37878311
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10600582
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Qaseem
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians (Version 2)
      </article-title>
      <source>
       Ann. Intern. Med.
      </source>
      <year>
       2023
      </year>
      <volume>
       176
      </volume>
      <fpage>
       1092
      </fpage>
      <lpage>
       1100
      </lpage>
      <pub-id pub-id-type="doi">
       10.7326/M23-0779
      </pub-id>
      <pub-id pub-id-type="pmid">
       37523709
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         BB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Plasma proteomic associations with genetics and health in the UK Biobank
      </article-title>
      <source>
       Nature
      </source>
      <year>
       2023
      </year>
      <volume>
       622
      </volume>
      <fpage>
       329
      </fpage>
      <lpage>
       338
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41586-023-06592-6
      </pub-id>
      <pub-id pub-id-type="pmid">
       37794186
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10567551
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXitVGqsbbJ
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ritchie
        </surname>
        <given-names>
         ME
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       limma powers differential expression analyses for RNA-sequencing and microarray studies
      </article-title>
      <source>
       Nucleic Acids Res.
      </source>
      <year>
       2015
      </year>
      <volume>
       43
      </volume>
      <fpage>
       e47
      </fpage>
      <pub-id pub-id-type="doi">
       10.1093/nar/gkv007
      </pub-id>
      <pub-id pub-id-type="pmid">
       25605792
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4402510
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fernandez-Rozadilla
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
      </article-title>
      <source>
       Nat. Genet.
      </source>
      <year>
       2023
      </year>
      <volume>
       55
      </volume>
      <fpage>
       89
      </fpage>
      <lpage>
       99
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41588-022-01222-9
      </pub-id>
      <pub-id pub-id-type="pmid">
       36539618
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XjtFCktr7L
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Privé
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         Arbel
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Vilhjálmsson
        </surname>
        <given-names>
         BJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       LDpred2: better, faster, stronger
      </article-title>
      <source>
       Bioinformatics
      </source>
      <year>
       2021
      </year>
      <volume>
       36
      </volume>
      <fpage>
       5424
      </fpage>
      <lpage>
       5431
      </lpage>
      <pub-id pub-id-type="doi">
       10.1093/bioinformatics/btaa1029
      </pub-id>
      <pub-id pub-id-type="pmid">
       33326037
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kuhn
        </surname>
        <given-names>
         M
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Building predictive models in R using the caret package
      </article-title>
      <source>
       J. Stat. Softw.
      </source>
      <year>
       2008
      </year>
      <volume>
       28
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       26
      </lpage>
      <pub-id pub-id-type="doi">
       10.18637/jss.v028.i05
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="other">
      Gerds, T., Ohlendorff, J. &amp; Ozenne, B.
      <italic>
       riskRegression: risk regression models and prediction scores for survival analysis with competing risks
      </italic>
      . R package version 2023.09.08 (2023).
      <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=riskRegression">
       https://CRAN.R-project.org/package=riskRegression
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR34">
     <label>
      34.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Vickers
        </surname>
        <given-names>
         AJ
        </given-names>
       </name>
       <name>
        <surname>
         Elkin
        </surname>
        <given-names>
         EB
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Decision curve analysis: a novel method for evaluating prediction models
      </article-title>
      <source>
       Med. Decis. Mak.
      </source>
      <year>
       2006
      </year>
      <volume>
       26
      </volume>
      <fpage>
       565
      </fpage>
      <lpage>
       574
      </lpage>
      <pub-id pub-id-type="doi">
       10.1177/0272989X06295361
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR35">
     <label>
      35.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Liese
        </surname>
        <given-names>
         AD
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Assessing the impact of classical risk factors on myocardial infarction by rate advancement periods
      </article-title>
      <source>
       Am. J. Epidemiol.
      </source>
      <year>
       2000
      </year>
      <volume>
       152
      </volume>
      <fpage>
       884
      </fpage>
      <lpage>
       888
      </lpage>
      <pub-id pub-id-type="doi">
       10.1093/aje/152.9.884
      </pub-id>
      <pub-id pub-id-type="pmid">
       11085401
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BD3M%2FkslCrtg%3D%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR36">
     <label>
      36.
     </label>
     <mixed-citation publication-type="other">
      Zheng, Y. et al. Use of breast cancer risk factors to identify risk-adapted starting age of screening in China.
      <italic>
       JAMA Netw. Open
      </italic>
      <bold>
       5
      </bold>
      , e2241441 (2022).
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec29">
     <title>
      补充信息
     </title>
     <p id="Par40">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Description of Additional Supplementary Files
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM4_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Supplementary Data 1-9
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM5_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec30">
     <title>
      源数据
     </title>
     <p id="Par41">
      <supplementary-material content-type="local-data" id="MOESM6" xlink:title="Source data">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM6_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Source Data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    补充信息
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-024-52894-2">
     https://doi.org/10.1038/s41467-024-52894-2
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
